Santen Pharmaceutical Co Ltd
TSE:4536

Watchlist Manager
Santen Pharmaceutical Co Ltd Logo
Santen Pharmaceutical Co Ltd
TSE:4536
Watchlist
Price: 1 670.5 JPY 0.39% Market Closed
Market Cap: 606.7B JPY
Have any thoughts about
Santen Pharmaceutical Co Ltd?
Write Note

Santen Pharmaceutical Co Ltd
Unrealized Security Profit/Loss

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Santen Pharmaceutical Co Ltd
Unrealized Security Profit/Loss Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Unrealized Security Profit/Loss CAGR 3Y CAGR 5Y CAGR 10Y
Santen Pharmaceutical Co Ltd
TSE:4536
Unrealized Security Profit/Loss
ÂĄ5.3B
CAGR 3-Years
-24%
CAGR 5-Years
N/A
CAGR 10-Years
1%
Takeda Pharmaceutical Co Ltd
TSE:4502
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Daiichi Sankyo Co Ltd
TSE:4568
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Otsuka Holdings Co Ltd
TSE:4578
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chugai Pharmaceutical Co Ltd
TSE:4519
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Unrealized Security Profit/Loss
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Santen Pharmaceutical Co Ltd
Glance View

Market Cap
594.1B JPY
Industry
Pharmaceuticals

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. The company is headquartered in Osaka, Osaka-Fu and currently employs 4,229 full-time employees. The firm has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The firm engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The firm operates in Japan, Europe, Asia, North America markets.

Intrinsic Value
2 142.23 JPY
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Santen Pharmaceutical Co Ltd's Unrealized Security Profit/Loss?
Unrealized Security Profit/Loss
5.3B JPY

Based on the financial report for Jun 30, 2024, Santen Pharmaceutical Co Ltd's Unrealized Security Profit/Loss amounts to 5.3B JPY.

What is Santen Pharmaceutical Co Ltd's Unrealized Security Profit/Loss growth rate?
Unrealized Security Profit/Loss CAGR 10Y
1%

Over the last year, the Unrealized Security Profit/Loss growth was -41%. The average annual Unrealized Security Profit/Loss growth rates for Santen Pharmaceutical Co Ltd have been -24% over the past three years , and 1% over the past ten years .

Back to Top